Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial

@article{Schmidt2005MethylxanthineTF,
  title={Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial},
  author={B. Schmidt},
  journal={Neonatology},
  year={2005},
  volume={88},
  pages={208 - 213}
}
  • B. Schmidt
  • Published 2005
  • Medicine
  • Neonatology
  • Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation. Recent research has raised concerns about the safety of methylxanthines in very preterm infants. Possible adverse effects include poor growth, worsening of hypoxic-ischemic brain damage and abnormal childhood behavior. Over 2,000 infants with birth weights 500–1,250 g have been randomized in the international placebo-controlled Caffeine for Apnea of Prematurity (CAP) trial to examine the long-term… CONTINUE READING
    Caffeine therapy for apnea of prematurity.
    549
    Current management of apnea in premature infants: is caffeine the magic bullet?
    5
    Caffeine therapy for apnoea of prematurity: Pharmacological treatment
    19

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 61 REFERENCES